CRT 2024

Moderated Discussion: Embolic Protection for All TAVR Patients - The Pros and Cons

Panel Moderator(s)

• 

  David J. Cohen, MD, FSCAI

  Director of Clinical and Outcomes Research
  Cardiovascular Research Foundation
  New York, New York, United States

  No relationships to disclose
• 

  Samir R. Kapadia, MD, FSCAI

  Chairman, Cardiovascular Medicine
  Cleveland Clinic
  Cleveland, Ohio, United States

  No relationships to disclose
• 

  Alexandra J. Lansky, MD, FACC, FAHA, FSCAI, FESC

  Professor of Medicine
  Yale School of Medicine
  New Haven, Connecticut, United States

  No relationships to disclose

Panel Discussant(s)

• 

  James E. Harvey, III, MD

  VP and CMO - Heart & Vascular Service Line
  WellSpan Health

  Disclosure(s): Abiomed Inc: Consultant (Ongoing); Boston Scientific Corporation: Consultant/Advisory Board (Ongoing); Medtronic: Consultant/Advisory Board (Ongoing), Speakers' Bureau (Ongoing)
• 

  Issam Moussa, MD

  Medical Director, Carle Heart & Vascular Institte
  Carle Health / University of Illinois Urbana Champaign
  Rancho Palos Verdes, California, United States

  No relationships to disclose
• 

  Giora Weisz, MD

  Interventional Cardiology
  NewYork Presbyterian Hospital - Columbia University Medical Center
  New York, New York, United States

  Disclosure(s): Filterlex: Advisory Committee/Board Member (Ongoing), Major Stockholder (not including mutual funds) (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing)